Aeon biopharma announces strategic resource reprioritization and cost reduction plan

Current cash and cash equivalents expected to be sufficient to support corporate operations into q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline current cash and cash equivalents expected to be sufficient to support corporate operations into q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline
AEON Ratings Summary
AEON Quant Ranking